Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.
Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.
Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Durham, N.C.-based Precision BioSciences set the company’s initial public offering price at $16 per share, raising $126.4 million.
Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.
Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.
Activist hedge fund Starboard Value LP asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co. shareholders for the U.S. drug maker’s $74 billion deal to buy Celgene Corp., people familiar with the matter said.